1. Home
  2. NIU vs INDP Comparison

NIU vs INDP Comparison

Compare NIU & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Niu Technologies

NIU

Niu Technologies

HOLD

Current Price

$2.05

Market Cap

200.8M

ML Signal

HOLD

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$0.98

Market Cap

171.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NIU
INDP
Founded
2014
2000
Country
China
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
200.8M
171.9M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
NIU
INDP
Price
$2.05
$0.98
Analyst Decision
Hold
Analyst Count
1
0
Target Price
$3.50
N/A
AVG Volume (30 Days)
224.5K
123.8K
Earning Date
05-18-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$25.54
N/A
Revenue Next Year
$17.70
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.93
$0.92
52 Week High
$5.67
$8.57

Technical Indicators

Market Signals
Indicator
NIU
INDP
Relative Strength Index (RSI) 34.52 26.94
Support Level N/A $0.92
Resistance Level $2.40 $2.95
Average True Range (ATR) 0.10 0.16
MACD -0.06 -0.01
Stochastic Oscillator 6.19 0.73

Price Performance

Historical Comparison
NIU
INDP

About NIU Niu Technologies

Niu Technologies designs, manufactures, and sells high-performance electric motorcycles, scooters, bicycles, and kick-scooters. The company has a product portfolio consisting of electric motorcycles, mopeds, and bicycle series, including the NQi, MQi, UQi, FQi series, and others, and micro-mobility series, including the kick-scooter series KQi and the e-bike series BQi. The company's principal operations and geographic markets are predominantly in the People's Republic of China. It also generates revenue from Europe and other regions.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Share on Social Networks: